The horse is at the stable door: management of N1M0 prostate cancer
AffiliationDivision of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractPelvic lymph node involvement in prostate cancer is a significant poor prognostic factor with very little evidence on the optimal management options for these patients. It is estimated that lymph node-positive patients make up 12% of newly diagnosed prostate cancer and this figure is expected to rise with the advancement and increasing use of novel imaging. The controversy around this subgroup of patients is whether this is an intermediary stage before disseminated disease and hence amenable to curative treatment options. Systemic therapies have been the mainstay of treatment for these patients for decades, but in recent years, studies have emerged supporting the addition of local therapy. This review will focus on the current multimodal management approach for clinical and pathological lymph node-positive prostate cancer with a focus on radiotherapy options and aims to provide the rationale for a curative approach with a combination of local and systemic therapy.
CitationThiruthaneeswaran N, Hayden AJ, Choudhury A. The Horse is at the Stable Door: Management of N1M0 Prostate Cancer. Clin Oncol (R Coll Radiol). 2019.
- Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
- Authors: Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ
- Issue date: 2020 Feb
- Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.
- Authors: Liskamp CP, Donswijk ML, van der Poel HG, Schaake EE, Vogel WV
- Issue date: 2020 May
- PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
- Authors: Shakespeare TP, Eggert E, Wood M, Westhuyzen J, Turnbull K, Rutherford N, Aherne N
- Issue date: 2019 Dec
- High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
- Authors: Rahman LA, Rutagengwa D, Lin P, Lin M, Yap J, Lai K, Mancuso P, Rathore P, Haghighi K, Gassner P, Wong LH, Lalak N
- Issue date: 2019 Dec 11
- Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.
- Authors: Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Sidhom M, Skala M, Yaxley J, Shakespeare TP
- Issue date: 2019 Nov